Creative Medical Technology (NASDAQ:CELZ) Announces Quarterly Earnings Results, Misses Estimates By $0.43 EPS

Creative Medical Technology (NASDAQ:CELZ) posted its quarterly earnings results on Friday. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.43), FiscalAI reports. The business had revenue of $0.00 million for the quarter.

Creative Medical Technology Trading Down 2.1%

Shares of Creative Medical Technology stock opened at $1.84 on Friday. Creative Medical Technology has a 52 week low of $1.50 and a 52 week high of $6.25. The stock has a market cap of $4.75 million, a PE ratio of -0.63 and a beta of 2.09. The company’s 50-day moving average price is $1.93 and its two-hundred day moving average price is $2.62.

Institutional Trading of Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Jane Street Group LLC purchased a new position in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned approximately 1.17% of Creative Medical Technology at the end of the most recent quarter. 1.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Creative Medical Technology in a report on Monday, December 29th. Wall Street Zen cut Creative Medical Technology from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Creative Medical Technology currently has an average rating of “Reduce”.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.